Copyright Reports & Markets. All rights reserved.

Global Ophthalmology Disorders Drug Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Oral
      • 1.4.3 Injection
      • 1.4.4 External Use
    • 1.5 Market by Application
      • 1.5.1 Global Ophthalmology Disorders Drug Market Share by Application (2019-2025)
      • 1.5.2 Juvenile Macular Degeneration (Stargardt Disease)
      • 1.5.3 Leber Congenital Amaurosis (LCA)
      • 1.5.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
      • 1.5.5 Usher Syndrome
      • 1.5.6 Retinitis Pigmentosa (Retinitis)
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Ophthalmology Disorders Drug Market Size
    • 2.2 Ophthalmology Disorders Drug Growth Trends by Regions
      • 2.2.1 Ophthalmology Disorders Drug Market Size by Regions (2019-2025)
      • 2.2.2 Ophthalmology Disorders Drug Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Ophthalmology Disorders Drug Market Size by by Players
      • 3.1.1 Global Ophthalmology Disorders Drug Revenue by by Players (2014-2019)
      • 3.1.2 Global Ophthalmology Disorders Drug Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Ophthalmology Disorders Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Ophthalmology Disorders Drug Key Players Head office and Area Served
    • 3.3 Key Players Ophthalmology Disorders Drug Product/Solution/Service
    • 3.4 Date of Enter into Ophthalmology Disorders Drug Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Ophthalmology Disorders Drug Market Size by Type (2014-2019)
    • 4.2 Global Ophthalmology Disorders Drug Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Ophthalmology Disorders Drug Market Size (2014-2019)
    • 5.2 Ophthalmology Disorders Drug Key Players in North America
    • 5.3 North America Ophthalmology Disorders Drug Market Size by Type
    • 5.4 North America Ophthalmology Disorders Drug Market Size by Application

    6 Europe

    • 6.1 Europe Ophthalmology Disorders Drug Market Size (2014-2019)
    • 6.2 Ophthalmology Disorders Drug Key Players in Europe
    • 6.3 Europe Ophthalmology Disorders Drug Market Size by Type
    • 6.4 Europe Ophthalmology Disorders Drug Market Size by Application

    7 China

    • 7.1 China Ophthalmology Disorders Drug Market Size (2014-2019)
    • 7.2 Ophthalmology Disorders Drug Key Players in China
    • 7.3 China Ophthalmology Disorders Drug Market Size by Type
    • 7.4 China Ophthalmology Disorders Drug Market Size by Application

    8 Japan

    • 8.1 Japan Ophthalmology Disorders Drug Market Size (2014-2019)
    • 8.2 Ophthalmology Disorders Drug Key Players in Japan
    • 8.3 Japan Ophthalmology Disorders Drug Market Size by Type
    • 8.4 Japan Ophthalmology Disorders Drug Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Ophthalmology Disorders Drug Market Size (2014-2019)
    • 9.2 Ophthalmology Disorders Drug Key Players in Southeast Asia
    • 9.3 Southeast Asia Ophthalmology Disorders Drug Market Size by Type
    • 9.4 Southeast Asia Ophthalmology Disorders Drug Market Size by Application

    10 India

    • 10.1 India Ophthalmology Disorders Drug Market Size (2014-2019)
    • 10.2 Ophthalmology Disorders Drug Key Players in India
    • 10.3 India Ophthalmology Disorders Drug Market Size by Type
    • 10.4 India Ophthalmology Disorders Drug Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Ophthalmology Disorders Drug Market Size (2014-2019)
    • 11.2 Ophthalmology Disorders Drug Key Players in Central & South America
    • 11.3 Central & South America Ophthalmology Disorders Drug Market Size by Type
    • 11.4 Central & South America Ophthalmology Disorders Drug Market Size by Application

    12 International Players Profiles

    • 12.1 Sanofi
      • 12.1.1 Sanofi Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Ophthalmology Disorders Drug Introduction
      • 12.1.4 Sanofi Revenue in Ophthalmology Disorders Drug Business (2014-2019))
      • 12.1.5 Sanofi Recent Development
    • 12.2 Bayer
      • 12.2.1 Bayer Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Ophthalmology Disorders Drug Introduction
      • 12.2.4 Bayer Revenue in Ophthalmology Disorders Drug Business (2014-2019)
      • 12.2.5 Bayer Recent Development
    • 12.3 Bausch + Lomb
      • 12.3.1 Bausch + Lomb Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Ophthalmology Disorders Drug Introduction
      • 12.3.4 Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2014-2019)
      • 12.3.5 Bausch + Lomb Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Ophthalmology Disorders Drug Introduction
      • 12.4.4 Novartis Revenue in Ophthalmology Disorders Drug Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 Usher Syndrome
      • 12.5.1 Usher Syndrome Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Ophthalmology Disorders Drug Introduction
      • 12.5.4 Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2014-2019)
      • 12.5.5 Usher Syndrome Recent Development
    • 12.6 Takeda Pharmaceutical
      • 12.6.1 Takeda Pharmaceutical Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Ophthalmology Disorders Drug Introduction
      • 12.6.4 Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2014-2019)
      • 12.6.5 Takeda Pharmaceutical Recent Development
    • 12.7 Roche
      • 12.7.1 Roche Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Ophthalmology Disorders Drug Introduction
      • 12.7.4 Roche Revenue in Ophthalmology Disorders Drug Business (2014-2019)
      • 12.7.5 Roche Recent Development
    • 12.8 Pfizer
      • 12.8.1 Pfizer Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Ophthalmology Disorders Drug Introduction
      • 12.8.4 Pfizer Revenue in Ophthalmology Disorders Drug Business (2014-2019)
      • 12.8.5 Pfizer Recent Development
    • 12.9 Allergan
      • 12.9.1 Allergan Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Ophthalmology Disorders Drug Introduction
      • 12.9.4 Allergan Revenue in Ophthalmology Disorders Drug Business (2014-2019)
      • 12.9.5 Allergan Recent Development
    • 12.10 Gilead Sciences
      • 12.10.1 Gilead Sciences Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Ophthalmology Disorders Drug Introduction
      • 12.10.4 Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2014-2019)
      • 12.10.5 Gilead Sciences Recent Development
    • 12.11 Kubota Pharmaceutical
    • 12.12 Alkeus Pharmaceuticals
    • 12.13 Astellas Pharma
    • 12.14 Ferrer Corporate
    • 12.15 Amgen Inc
    • 12.16 Editas Medicine Inc
    • 12.17 ProQR Therapeutics NV
    • 12.18 ReNeuron
    • 12.19 Amarantus BioScience
    • 12.20 Ocugen
    • 12.21 ReGenX Biosciences
    • 12.22 Sucampo Pharmaceuticals
    • 12.23 Orphagen Pharmaceuticals
    • 12.24 Okuvision
    • 12.25 Second Sight Medical
    • 12.26 Acucela
    • 12.27 Stealth BioTherapeutics
    • 12.28 Sun Pharma Advanced Research Company
    • 12.28 AmpliPhi Biosciences
    • 12.40 Applied Genetic Technologies
    • 12.31 Asklepios BioPharmaceutical
    • 12.32 Biovista
    • 12.33 Spark Therapeutics
    • 12.34 Caladrius Biosciences
    • 12.35 Dompe Farmaceutici
    • 12.36 Dormant Projects
    • 12.37 Grupo Ferrer Internacional
    • 12.38 ID Pharma
    • 12.39 InFlectis BioScience
    • 12.40 Ionis Pharmaceuticals
    • 12.41 Ixchel Pharma
    • 12.42 Khondrion
    • 12.43 Mimetogen Pharmaceuticals
    • 12.44 Mitotech
    • 12.45 M's Science
    • 12.46 Nanovector
    • 12.47 SanBio

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      This report focuses on the global Ophthalmology Disorders Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Ophthalmology Disorders Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Sanofi
      Bayer
      Bausch + Lomb
      Novartis
      Usher Syndrome
      Takeda Pharmaceutical
      Roche
      Pfizer
      Allergan
      Gilead Sciences
      Kubota Pharmaceutical
      Alkeus Pharmaceuticals
      Astellas Pharma
      Ferrer Corporate
      Amgen Inc
      Editas Medicine Inc
      ProQR Therapeutics NV
      ReNeuron
      Amarantus BioScience
      Ocugen
      ReGenX Biosciences
      Sucampo Pharmaceuticals
      Orphagen Pharmaceuticals
      Okuvision
      Second Sight Medical
      Acucela
      Stealth BioTherapeutics
      Sun Pharma Advanced Research Company
      AmpliPhi Biosciences
      Applied Genetic Technologies
      Asklepios BioPharmaceutical
      Biovista
      Spark Therapeutics
      Caladrius Biosciences
      Dompe Farmaceutici
      Dormant Projects
      Grupo Ferrer Internacional
      ID Pharma
      InFlectis BioScience
      Ionis Pharmaceuticals
      Ixchel Pharma
      Khondrion
      Mimetogen Pharmaceuticals
      Mitotech
      M's Science
      Nanovector
      SanBio

      Market segment by Type, the product can be split into
      Oral
      Injection
      External Use

      Market segment by Application, split into
      Juvenile Macular Degeneration (Stargardt Disease)
      Leber Congenital Amaurosis (LCA)
      Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
      Usher Syndrome
      Retinitis Pigmentosa (Retinitis)

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Ophthalmology Disorders Drug status, future forecast, growth opportunity, key market and key players.
      To present the Ophthalmology Disorders Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Ophthalmology Disorders Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now